BRIEF-Neurocrine Biosciences Q2 Adjusted EPS USD 2.85 Vs. IBES Estimate USD 1.34
Reuters2026/07/30 20:02Jul 30 (Reuters) - Neurocrine Biosciences Q2 EPS USD 1.39.
- Q2 adjusted net income USD 297 million vs. IBES estimate USD 141.4 million
- Q2 net income USD 144 million
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Why do tech stocks become "cheaper as they rise"? 80% profit surge supports valuations, but if AI expectations fall short, they will instantly become expensive.
In a bear market, it is usually necessary to smash stock prices to pieces with a hammer to make stocks cheaper. However, technology stocks have found another path.
EUR/JPY Price Forecast: Tests rising wedge bottom near 184.00
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
